About Us Services Careers FAQ Contact Us 0
Home Pharmaceuticals Global Osteoporosis Drugs Market Size to Reach USD 19.96 billion by 2033
Osteoporosis Drugs Market

Osteoporosis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, Others), By Route of Administration (Oral, Injectable) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRPH54591DR
Author : Debashree Bora
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Osteoporosis Drugs Market Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Bisphosphonates
        1. By Value
      3. Selective Estrogen Inhibitors Modulator (SERM)
        1. By Value
      4. Parathyroid Hormone Therapy
        1. By Value
      5. Calcitonin
        1. By Value
      6. Rank Ligand Inhibitors
        1. By Value
      7. Others
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectable
        1. By Value
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Bisphosphonates
        1. By Value
      3. Selective Estrogen Inhibitors Modulator (SERM)
        1. By Value
      4. Parathyroid Hormone Therapy
        1. By Value
      5. Calcitonin
        1. By Value
      6. Rank Ligand Inhibitors
        1. By Value
      7. Others
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectable
        1. By Value
    4. U.S.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Bisphosphonates
          1. By Value
        3. Selective Estrogen Inhibitors Modulator (SERM)
          1. By Value
        4. Parathyroid Hormone Therapy
          1. By Value
        5. Calcitonin
          1. By Value
        6. Rank Ligand Inhibitors
          1. By Value
        7. Others
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectable
          1. By Value
    5. Canada
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Bisphosphonates
        1. By Value
      3. Selective Estrogen Inhibitors Modulator (SERM)
        1. By Value
      4. Parathyroid Hormone Therapy
        1. By Value
      5. Calcitonin
        1. By Value
      6. Rank Ligand Inhibitors
        1. By Value
      7. Others
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectable
        1. By Value
    4. U.K.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Bisphosphonates
          1. By Value
        3. Selective Estrogen Inhibitors Modulator (SERM)
          1. By Value
        4. Parathyroid Hormone Therapy
          1. By Value
        5. Calcitonin
          1. By Value
        6. Rank Ligand Inhibitors
          1. By Value
        7. Others
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectable
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Bisphosphonates
        1. By Value
      3. Selective Estrogen Inhibitors Modulator (SERM)
        1. By Value
      4. Parathyroid Hormone Therapy
        1. By Value
      5. Calcitonin
        1. By Value
      6. Rank Ligand Inhibitors
        1. By Value
      7. Others
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectable
        1. By Value
    4. China
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Bisphosphonates
          1. By Value
        3. Selective Estrogen Inhibitors Modulator (SERM)
          1. By Value
        4. Parathyroid Hormone Therapy
          1. By Value
        5. Calcitonin
          1. By Value
        6. Rank Ligand Inhibitors
          1. By Value
        7. Others
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectable
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Taiwan
    10. South East Asia
    11. Rest of Asia-Pacific
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Bisphosphonates
        1. By Value
      3. Selective Estrogen Inhibitors Modulator (SERM)
        1. By Value
      4. Parathyroid Hormone Therapy
        1. By Value
      5. Calcitonin
        1. By Value
      6. Rank Ligand Inhibitors
        1. By Value
      7. Others
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectable
        1. By Value
    4. UAE
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Bisphosphonates
          1. By Value
        3. Selective Estrogen Inhibitors Modulator (SERM)
          1. By Value
        4. Parathyroid Hormone Therapy
          1. By Value
        5. Calcitonin
          1. By Value
        6. Rank Ligand Inhibitors
          1. By Value
        7. Others
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectable
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Bisphosphonates
        1. By Value
      3. Selective Estrogen Inhibitors Modulator (SERM)
        1. By Value
      4. Parathyroid Hormone Therapy
        1. By Value
      5. Calcitonin
        1. By Value
      6. Rank Ligand Inhibitors
        1. By Value
      7. Others
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectable
        1. By Value
    4. Brazil
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Bisphosphonates
          1. By Value
        3. Selective Estrogen Inhibitors Modulator (SERM)
          1. By Value
        4. Parathyroid Hormone Therapy
          1. By Value
        5. Calcitonin
          1. By Value
        6. Rank Ligand Inhibitors
          1. By Value
        7. Others
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectable
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Osteoporosis Drugs Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Amgen Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Eli Lilly and Company
    3. F. Hoffmann-La Roche Ltd.
    4. Radius Health Inc.
    5. Merck & Co., Inc.
    6. Novartis AG
    7. Pfizer Inc.
    8. Sun Pharmaceutical Industries Ltd.
    9. Takeda Pharmaceutical Company Limited
    10. Teva Pharmaceutical Industries Ltd.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global psoriasis drug market was valued at USD 12.35 billion in 2023. It is estimated to reach USD 32.89 billion by 2032, growing at a CAGR of 11.50% during the forecast period (2024–2032). The global psoriasis drug market is primarily driv
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.